trial

A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal

NCTId NCT03666715
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 55 (actual)
Sponsored by Janssen-Cilag Farmaceutica Ltda.
Primary completion 2021-05-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
55 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2018-08-07
Primary completion
2021-05-31
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Oral Antipsychotics (OAPs)Paliperidone

Sponsors

Janssen-Cilag Farmaceutica Ltda.Lead Sponsor

Sites

1 total
Porto, Portugal

Facts & assertions

4 sourced
Enrollment
55
Phase
NA
Primary Completion Date
2021-05-31
Status
COMPLETED
relationships
The graph out of here
drug
Oral Antipsychotics (OAPs)
drug
Paliperidone
drug
lead_sponsor
Janssen-Cilag Farmaceutica Ltda.
company
indication
Schizophrenia
indication
Schizophrenia
indication